MedTrace Logo

Salvage Surgery for Patients With Metastatic GIST With Rego

NCT04343456 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2020-04-14

No results posted yet for this study

Summary

Some researches have shown surgery may acquire progression-free (PFS) benefit for selected patients with metastatic gastrointestinal stromal tumor (GIST) who received first-line imatinib and second-line sunitinib. However, impact of salvage surgery on pre-treated GIST patients receiving third-line regorafenib facing progression is not yet reported. Investigators retrospectively reviewed patients with regorafenib treatment with salvage surgery.

Conditions

Interventions

PROCEDURE

Salvage surgery with massive debulking

For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Chun Nan Yeh, MD. · Chang Gung Memorial Hospital, Linkuo

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2019-12-31
Completion
2020-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343456 on ClinicalTrials.gov